318 related articles for article (PubMed ID: 3883097)
1. alpha-Glucosidase inhibition improves postprandial hyperglycemia and decreases insulin requirements in insulin-dependent diabetes mellitus.
Dimitriadis GD; Tessari P; Go VL; Gerich JE
Metabolism; 1985 Mar; 34(3):261-5. PubMed ID: 3883097
[TBL] [Abstract][Full Text] [Related]
2. Effects of a long-acting somatostatin analogue on postprandial hyperglycemia in insulin-dependent diabetes mellitus.
Dimitriadis G; Tessari P; Gerich J
Metabolism; 1983 Oct; 32(10):987-92. PubMed ID: 6136893
[TBL] [Abstract][Full Text] [Related]
3. Effects of prolonged (6 months) alpha-glucosidase inhibition on blood glucose control and insulin requirements in patients with insulin-dependent diabetes mellitus.
Dimitriadis G; Karaiskos C; Raptis S
Horm Metab Res; 1986 Apr; 18(4):253-5. PubMed ID: 3519413
[TBL] [Abstract][Full Text] [Related]
4. Combined use of guar and acarbose in reduction of postprandial glycaemia.
Jenkins DJ; Taylor RH; Nineham R; Goff DV; Bloom SR; Sarson D; Alberti KG
Lancet; 1979 Nov; 2(8149):924-7. PubMed ID: 91023
[TBL] [Abstract][Full Text] [Related]
5. Optimum effectiveness of intestinal alpha-glucosidase inhibitors: importance of uniform distribution through a meal.
O'Dea K; Turton J
Am J Clin Nutr; 1985 Mar; 41(3):511-6. PubMed ID: 3883743
[TBL] [Abstract][Full Text] [Related]
6. Improvement of metabolic control in insulin dependent diabetics treated with the alpha-glucosidase inhibitor acarbose for two months.
Gérard J; Luyckx AS; Lefebvre PJ
Diabetologia; 1981 Nov; 21(5):446-51. PubMed ID: 7028558
[TBL] [Abstract][Full Text] [Related]
7. A risk-benefit appraisal of acarbose in the management of non-insulin-dependent diabetes mellitus.
Santeusanio F; Compagnucci P
Drug Saf; 1994 Dec; 11(6):432-44. PubMed ID: 7727053
[TBL] [Abstract][Full Text] [Related]
8. Comparing the efficacy of α-glucosidase inhibitors in suppressing postprandial hyperglycemia using continuous glucose monitoring: a pilot study-the MAJOR study.
Tsujino D; Nishimura R; Taki K; Morimoto A; Tajima N; Utsunomiya K
Diabetes Technol Ther; 2011 Mar; 13(3):303-8. PubMed ID: 21291335
[TBL] [Abstract][Full Text] [Related]
9. Improved metabolic profiles in insulin-treated diabetic patients given an alpha-glucosidehydrolase inhibitor.
Walton RJ; Sherif IT; Noy GA; Alberti KG
Br Med J; 1979 Jan; 1(6158):220-1. PubMed ID: 369651
[TBL] [Abstract][Full Text] [Related]
10. Alpha-glucosidase inhibition and timing of preprandial insulin in patients with insulin-dependent diabetes mellitus (IDDM).
Kennedy FP; Gerich JE
Diabetes Res Clin Pract; 1988 Apr; 4(4):309-12. PubMed ID: 3286168
[TBL] [Abstract][Full Text] [Related]
11. The effects of an alpha-glucoside hydrolase inhibitor on glycemia and the absorption of sucrose in man determined using a tracer method.
Radziuk J; Kemmer F; Morishima T; Berchtold P; Vranic M
Diabetes; 1984 Mar; 33(3):207-13. PubMed ID: 6365657
[TBL] [Abstract][Full Text] [Related]
12. Low-dose acarbose improves glycemic control in NIDDM patients without changes in insulin sensitivity.
Jenney A; Proietto J; O'Dea K; Nankervis A; Traianedes K; D'Embden H
Diabetes Care; 1993 Feb; 16(2):499-502. PubMed ID: 8432223
[TBL] [Abstract][Full Text] [Related]
13. Reduction of carbohydrate-induced hypertriglyceridemia in (fa,fa) "Zucker" rats by the alpha-glucosidase inhibitor acarbose (BAY g 5421).
Krause HP; Keup U; Thomas G; Puls W
Metabolism; 1982 Jul; 31(7):710-4. PubMed ID: 7045575
[TBL] [Abstract][Full Text] [Related]
14. The effect of chronic alpha-glycosidase inhibition on diabetic nephropathy in the db/db mouse.
Lee SM
Diabetes; 1982 Mar; 31(3):249-54. PubMed ID: 6759241
[TBL] [Abstract][Full Text] [Related]
15. Inhibitory effect of black tea and its combination with acarbose on small intestinal α-glucosidase activity.
Satoh T; Igarashi M; Yamada S; Takahashi N; Watanabe K
J Ethnopharmacol; 2015 Feb; 161():147-55. PubMed ID: 25523370
[TBL] [Abstract][Full Text] [Related]
16. [Acarbose--a new therapeutic principle in diabetes mellitus therapy].
Schöffling K; Hillebrand I
Dtsch Med Wochenschr; 1981 Aug; 106(35):1083-4. PubMed ID: 6114844
[No Abstract] [Full Text] [Related]
17. Effects of the alpha-glucosidase inhibitor acarbose on postprandial serum glucose and insulin concentrations in healthy dogs.
Robertson J; Nelson R; Kass P; Neal L
Am J Vet Res; 1999 May; 60(5):541-5. PubMed ID: 10328421
[TBL] [Abstract][Full Text] [Related]
18. A review of the safety and efficacy of acarbose in diabetes mellitus.
Yee HS; Fong NT
Pharmacotherapy; 1996; 16(5):792-805. PubMed ID: 8888075
[TBL] [Abstract][Full Text] [Related]
19. Use of an alpha-glucosidase inhibitor to maintain glucose homoeostasis during postprandial exercise in intensively treated Type 1 diabetic subjects.
Rabasa-Lhoret R; Burelle Y; Ducros F; Bourque J; Lavoie C; Massicotte D; Péronnet F; Chiasson JL
Diabet Med; 2001 Sep; 18(9):739-44. PubMed ID: 11606172
[TBL] [Abstract][Full Text] [Related]
20. The effects of the alpha-glucosidase inhibitor BAY g 5421 (Acarbose) on meal-stimulated elevations of circulating glucose, insulin, and triglyceride levels in man.
Hillebrand I; Boehme K; Frank G; Fink H; Berchtold P
Res Exp Med (Berl); 1979 Apr; 175(1):81-6. PubMed ID: 375342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
